Phreesia, Inc. (NYSE:PHR) Receives Average Recommendation of “Buy” from Analysts

Phreesia, Inc. (NYSE:PHR) has been assigned an average rating of “Buy” from the twelve brokerages that are covering the stock, MarketBeat Ratings reports. Twelve research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $31.33.

A number of equities research analysts have recently issued reports on the company. KeyCorp lowered their target price on Phreesia from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Wednesday, April 16th. Canaccord Genuity Group lifted their price objective on shares of Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, March 13th. DA Davidson dropped their price target on shares of Phreesia from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Monday, April 14th. Needham & Company LLC reissued a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a research report on Thursday, March 13th. Finally, Piper Sandler restated an “overweight” rating and set a $33.00 target price (up from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th.

Phreesia Stock Up 0.2%

PHR opened at $25.45 on Wednesday. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The business has a 50 day moving average price of $25.32 and a two-hundred day moving average price of $25.08. Phreesia has a 52 week low of $17.07 and a 52 week high of $30.53. The company has a market cap of $1.51 billion, a PE ratio of -17.31 and a beta of 0.74.

Insider Buying and Selling at Phreesia

In other news, SVP David Linetsky sold 4,499 shares of the firm’s stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $23.73, for a total transaction of $106,761.27. Following the sale, the senior vice president now owns 217,239 shares of the company’s stock, valued at $5,155,081.47. This trade represents a 2.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Balaji Gandhi sold 1,827 shares of the company’s stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $27.46, for a total value of $50,169.42. Following the sale, the chief financial officer now owns 103,591 shares in the company, valued at $2,844,608.86. The trade was a 1.73% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,474 shares of company stock worth $1,023,208. Company insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Several large investors have recently made changes to their positions in PHR. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Phreesia by 108.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company’s stock worth $67,606,000 after acquiring an additional 1,377,904 shares during the period. American Century Companies Inc. increased its position in Phreesia by 3,741.9% during the 1st quarter. American Century Companies Inc. now owns 983,440 shares of the company’s stock worth $25,137,000 after purchasing an additional 957,842 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its stake in shares of Phreesia by 133.6% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,271,832 shares of the company’s stock valued at $31,999,000 after acquiring an additional 727,384 shares during the last quarter. Greenhouse Funds LLLP increased its stake in shares of Phreesia by 27.9% in the fourth quarter. Greenhouse Funds LLLP now owns 2,873,892 shares of the company’s stock valued at $72,307,000 after buying an additional 626,579 shares during the period. Finally, Nuveen LLC acquired a new position in Phreesia in the 1st quarter valued at approximately $14,206,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.